Al-Ibraheem A, Abdlkadir A, Albalooshi B, Muhsen H, Haidar M, Omar Y et al. Theranostics in the Arab world; achievements & challenges. Jordan Med J. 2022;56:1–13.

Al-Ibraheem A, Zimmermann R, Abdlkadir AS, Herrmann K. Radiotheranostics Global Market and Future Developments. Semin Nucl Med. 2024;54:622–33.

Article  PubMed  Google Scholar 

Jadvar H, Chen X, Cai W, Mahmood U. Radiotheranostics in cancer diagnosis and management. Radiology. 2018;286:388–400.

Article  PubMed  Google Scholar 

Sreedevi B, Kishore N, Ghosh S, Kaur G. Radiotheranostics in Oncology. Int J Trends OncoSci. 2024:19–26.

Al-Ibraheem A. Theranostics in Developing Countries: Addressing Challenges and Potentials from Training to Practice. World J Nucl Med. 2023;22:171–3.

Article  PubMed  PubMed Central  Google Scholar 

Li C, Wu Q, Sun S. Radioactive iodine therapy in patients with thyroid carcinoma with distant metastases: a SEER-based study. Cancer Control. 2020;27:1073274820914661.

Article  PubMed  PubMed Central  Google Scholar 

Al-Ibraheem A, Al-Shammaa M, Abdlkadir AS, Istatieh F, Al-Rasheed U, Pascual T, et al. Survival Trends in Pediatric Differentiated Thyroid Cancer: A Middle Eastern Perspective. Life. 2024;14:158.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Orosco RK, Hussain T, Noel JE, Chang DC, Dosiou C, Mittra E, et al. Radioactive iodine in differentiated thyroid cancer: a national database perspective. Endocr Relat Cancer. 2019;26:795–802.

Article  PubMed  PubMed Central  Google Scholar 

Al-Ibraheem A, Al-Rasheed U, Mashhadani N, Abdlkadir AS, Al-Adhami DA, Ruzzeh S, et al. Long-Term Survival Analysis and Prognostic Factors of Arabic Patients with Differentiated Thyroid Carcinoma: A 20-Year Observational Study at the King Hussein Cancer Center (KHCC) Involving 528 Patients. Cancers. 2023;15:4102.

Article  PubMed  PubMed Central  Google Scholar 

Urbain J-L, Scott AM, Lee ST, Buscombe J, Weston C, Hatazawa J, et al. Theranostic radiopharmaceuticals: a universal challenging educational paradigm in nuclear medicine. J Nucl Med. 2023;64:986–91.

Article  PubMed  CAS  Google Scholar 

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091–103.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hofman MS, Emmett L, Violet J, A YZ, Lawrence NJ, Stockler M et al. TheraP: a randomized phase 2 trial of (177) Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int. 2019;124 Suppl 1:5–13.

Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S et al. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022:1–11.

Cerci JJ, Fanti S, Lobato EE, Kunikowska J, Alonso O, Medina S, et al. Diagnostic performance and clinical impact of 68Ga-PSMA-11 PET/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA Study). J Nucl Med. 2022;63:240–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Velikyan I. Prospective of ⁶⁸Ga-radiopharmaceutical development. Theranostics. 2013;4:47–80.

Article  PubMed  PubMed Central  Google Scholar 

Müller C, Vermeulen C, Johnston K, Köster U, Schmid R, Türler A, van der Meulen NP. Preclinical in vivo application of (152)Tb-DOTANOC: a radiolanthanide for PET imaging. EJNMMI Res. 2016;6:35.

Article  PubMed  PubMed Central  Google Scholar 

Stokke C, Kvassheim M, Blakkisrud J. Radionuclides for targeted therapy: physical properties. Molecules. 2022;27:5429.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kossert K, Nähle OJ, Ott O, Dersch R. Activity determination and nuclear decay data of 177Lu. Appl Radiat Isot. 2012;70:2215–21.

Article  PubMed  CAS  Google Scholar 

Al-Ibraheem A, Scott AM. 161Tb-PSMA unleashed: a promising new player in the theranostics of prostate cancer. Nucl Med Mol Imaging. 2010;2023(57):168–71.

Google Scholar 

Müller C, Vermeulen C, Köster U, Johnston K, Türler A, Schibli R, van der Meulen NP. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. EJNMMI Radiopharm Chem. 2017;1:5.

Article  PubMed  Google Scholar 

Moiseeva AN, Aliev RA, Furkina EB, Novikov VI, Unezhev VN. New method for production of 155Tb via 155Dy by irradiation of natGd by medium energy alpha particles. Nucl Med Biol. 2022;106–107:52–61.

Article  PubMed  Google Scholar 

Favaretto C, Talip Z, Borgna F, Grundler PV, Dellepiane G, Sommerhalder A, et al. Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging. EJNMMI Radiopharm Chem. 2021;6:1–17.

Article  Google Scholar 

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009; 339 (jul21 1), b2700–b2700

Fricke J, Westerbergh F, McDougall L, Favaretto C, Christ E, Nicolas GP et al. First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161 Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum. Eur J Nucl Med Mol Imaging. 2024;51:2517–2.

Al-Ibraheem A, Doudeen RM, Juaidi D, Abufara A, Maus S. 161Tb-PSMA Radioligand Therapy: First-in-Humans SPECT/CT Imaging. J Nucl Med. 2023;64:1322–3.

Article  PubMed  Google Scholar 

Baum RP, Singh A, Kulkarni HR, Bernhardt P, Rydén T, Schuchardt C, et al. First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC. J Nucl Med. 2021;62:1391–7.

Article  PubMed  PubMed Central  Google Scholar 

Müller C, Singh A, Umbricht CA, Kulkarni HR, Johnston K, Bensova M, et al. Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer. EJNMMI Res. 2019;9:10.

Article  Google Scholar 

Baum RP, Singh A, Benešová M, Vermeulen C, Gnesin S, Köster U, et al. Clinical evaluation of the radiolanthanide terbium-152: First-in-human PET/CT with 152Tb-DOTATOC. Dalton Trans. 2017;46:14638–46.

Article  PubMed  CAS  Google Scholar 

Schaefer-Schuler A, Burgard C, Blickle A, Maus S, Petrescu C, Petto S, et al. [161Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]Lu-PSMA-617. Theranostics. 2024;14:1829–40.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rosar F, Maus S, Schaefer-Schuler A, Burgard C, Khreish F, Ezziddin S. New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC. Clin Nucl Med. 2023;48:433–4.

Article  PubMed  Google Scholar 

Al-Ibraheem A, Abdlkadir AS, Sweedat DA, Maus S, Al-Rasheed U, Salah S, et al. From Despair to Hope: First Arabic Experience of 177Lu-PSMA and 161Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer. Cancers. 2024;16:1974.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jüni P, Loke Y, Pigott T, Ramsay C, Regidor D, Rothstein H, et al. Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance. Br Med J. 2016;355: i4919.

Google Scholar 

Abdlkadir AS, Abufara A, Al-Ibraheem A. Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure. Nucl Med Mol Imaging. 2010;2024(58):1–3.

Google Scholar 

Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, et al. Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022;49:1113–26.

Article  PubMed  CAS  Google Scholar 

Naskar N, Lahiri S. Theranostic terbium radioisotopes: challenges in production for clinical application. Front Med. 2021;8:675014–3.

Müller C, van der Meulen NP, Schibli R. Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics. Eur J Nucl Med Mol Imaging. 2023;50:3181–4.

Article  PubMed  Google Scholar 

Favaretto C, Grundler PV, Talip Z, Landolt S, Sepini L, Köster U, et al. (161)Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of (161)Tb into the Clinic. J Nucl Med. 2023;64:1138–44.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ku A, Facca VJ, Cai Z, Reilly RM. Auger electrons for cancer therapy – a review. EJNMMI Radiopharm Chem. 2019;4:27.

Article  PubMed  PubMed Central